证券代码：605266 证券简称：健之佳 公告编号：2026-002 健之佳医药连锁集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | 本次担保金额 | 实际为其提供的 担保余额（不含本 | | 是否在前期预计 | 本次担保是否有 | | --- | --- | --- | --- | --- | --- | | | | 次担保金额） | | 额度内 | 反担保 | | | 1,000.00 万元 | 1,980.00 | 万元 | 是 | 否 | | 云南之佳便利店有 限公司 | | | | | | | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 | 194,357.40 | | 子公司对外担保总额（万元） | | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 69.48 | | 特别风险提示（如有请勾选） | 担保金额（含本次）超过上市公 ...

Core Insights - The strategic cooperation agreement between Innovent Biologics and Jianzhijia was officially signed on January 5, 2026, marking a significant partnership aimed at enhancing the distribution of innovative pharmaceuticals [1][2] - Innovent Biologics has achieved notable success in collaboration with Jianzhijia in 2025, particularly with the positive market feedback for its product, Sinleukin (Mastuzumab Injection), within Jianzhijia's retail network [1] - Jianzhijia aims to leverage its retail network and professional service capabilities to provide comprehensive health solutions by introducing high-quality drugs from innovative pharmaceutical companies like Innovent Biologics [1] Company Strategies - Innovent Biologics emphasizes the importance of retail channel development and plans to explore innovative drug development models in collaboration with Jianzhijia, focusing on patient education, pharmaceutical services, and medication tracking [2] - Jianzhijia's management has proposed specific collaboration directions, aiming to utilize its terminal network and professional service advantages for deeper cooperation in product promotion, patient management, and health services with Innovent Biologics [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 增持主体的基本情况：健之佳医药连锁集团股份有限公司（以下简称"公司"）实际控制人之一蓝波 100%控股的云南祥群投资有限公司（以下简称"云南祥群"）持有公司13,818,299股股份，占公司总股本 的8.9414%。含云南祥群在内，公司实际控制人蓝波、舒畅夫妇及其一致行动人合计持有公司 63,007,569股股份，占公司总股本的40.7703%。 ● 增持计划的主要内容：近日，公司收到云南祥群的《关于增持公司股份的告知函》，云南祥群拟自本 公告披露日起6个月内通过上海证券交易所交易系统以集中竞价交易方式增持公司A股股份，增持总金 额5,000万元，资金来源为自有资金及股票增持专项贷款。 本次增持计划不触及要约收购，不会导致公司控股股东及实际控制人发生变化。 ● 增持计划无法实施风险：可能存在因资本市场变化等目前尚无法预判的因素，导致本次增持计划无法 按期完成的风险，敬请广大投资者注意投资风险。 一、增 ...

Summary of Key Points Core Viewpoint - The report highlights the stock repurchase and reduction activities of various A-share listed companies as of December 31, indicating potential investment opportunities and market sentiment. Group 1: Stock Repurchase Activities - Luxshare Precision has obtained a commitment letter for a stock repurchase loan not exceeding 1.8 billion yuan [2] - Jiaze New Energy plans to repurchase shares worth between 220 million to 440 million yuan [2] - Jianzhijia's actual controller and concerted parties intend to increase their holdings by 50 million yuan [2] - Dagang Holdings plans to repurchase shares worth between 20 million to 40 million yuan [2] Group 2: Stock Reduction Activities - Liandong Technology's controlling shareholder and actual controller have cumulatively reduced their holdings by 2.98% [2] - ST Lutong's shareholder Wu Aijun plans to reduce holdings by no more than 3% [2] - Lingzhi Software's shareholder intends to reduce holdings by no more than 1.43% [2] - Green Island Wind's shareholder Zhenzhong Investment plans to reduce holdings by no more than 1.00% [2] - Shuanglin Shares' Huang Shichen intends to reduce holdings by no more than 0.02% [2]

Group 1 - Aerospace Power's main business does not involve commercial aerospace, nor does it have any commercial aerospace-related assets for external investment [1] - Daye Co., Ltd.'s robotic tendon products are still in the exploratory testing phase and have not yet achieved mass production [1] Group 2 - Zhongyan Chemical plans to invest 83.9692 million yuan to expand its production capacity to 10,000 tons of metallic sodium and 15,500 tons of liquid nitrogen annually [1] - Huakang Clean has won the bid for the construction of the laboratory process project (Phase I, first opening area) in Dalian Yinggeshi Science City [1] Group 3 - Lixun Precision intends to repurchase shares worth between 1 billion to 2 billion yuan [1] - Green Island Wind's actual controller's concerted actors plan to reduce their holdings by no more than 1% of shares [1] Group 4 - Guangku Technology expects a year-on-year net profit increase of 152.00% to 172.00% in 2025 [1] - Zhaoli Technology is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure [1]

Group 1: Company Announcements - Zhongwei Company plans to acquire 64.69% equity of Hangzhou Zhonggui through a combination of share issuance and cash payment, aiming to enhance its capabilities in CMP equipment and solutions [1] - Lixun Precision intends to repurchase shares worth between 1 billion to 2 billion RMB for employee stock ownership plans or equity incentives, with a maximum repurchase price of 86.96 RMB per share [2] - ZaiJing Pharmaceutical has reached a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, receiving an upfront payment of 100 million USD [3] - Tianci Materials expects a net profit increase of 127% to 231% for 2025, driven by significant growth in lithium-ion battery material sales [4] - Meike Home plans to acquire 100% equity of Shenzhen Wande Technology through share issuance and cash payment, with stock resuming trading on January 5, 2026 [6][7] - ST KeliDa is planning a change in control, with stock suspension starting January 5, 2026, due to the transfer of 100% equity of its controlling shareholder [8] - Xinzhou Bang intends to invest approximately 260 million USD in a lithium-ion battery materials project in Saudi Arabia, enhancing its global capacity and supply chain [9] Group 2: Financial Performance - Kid's King anticipates a net profit increase of 51.72% to 82.06% for 2025 [9] - Guangku Technology expects a net profit growth of 152% to 172% for 2025 [9] Group 3: Mergers and Acquisitions - Xidi Micro plans to acquire 100% equity of Chengxin Micro for 310 million RMB [9] - Haili Biological's subsidiary intends to acquire 51% equity of seven dental chain companies for 61.2 million RMB [9]

Group 1: Mergers and Acquisitions - Haili Biological's subsidiary, Ruisheng Biological, plans to invest 61.2 million yuan to acquire 51% equity in seven dental chain companies located in Yangzhou and Changzhou, which is expected to increase the company's revenue by approximately 100 million yuan and net profit by over 7 million yuan [1] - Yanggu Huatai has decided to terminate the issuance of shares and cash payment to acquire 99.64% equity in Bomi Technology, opting to negotiate for partial equity acquisition in cash instead [2] - Yachuang Electronics intends to issue shares and pay cash totaling 317 million yuan to purchase 40% equity in Shenzhen Ouchuang Semiconductor and 45% equity in Shenzhen Yihai Nengda, constituting a major asset restructuring [3] Group 2: Earnings Forecasts - Guangku Technology anticipates a net profit attributable to shareholders of 169 million to 182 million yuan for 2025, representing a year-on-year growth of 152% to 172% [4] Group 3: Shareholding Changes - Jianzhijia's actual controller, Yunnan Xiangqun, plans to increase its stake in the company by up to 2% through a concentrated bidding process, with an investment amount of 50 million yuan sourced from its own funds and a loan of up to 45 million yuan from CITIC Bank [5] - Zhenzhong Investment, a significant shareholder of Lvdiaofeng, plans to reduce its stake by no more than 1% through a concentrated bidding process, equating to a maximum of 680,000 shares [6] - Two shareholders of Lingzhi Software plan to reduce their holdings by a combined total of up to 1.43%, with one shareholder reducing by up to 3.281 million shares (0.82% of total shares) and the other by up to 2.4492 million shares (0.61% of total shares) [7] Group 4: Tax Issues - Tianyue Advanced announced that it needs to pay a total of 82.9728 million yuan in corporate income tax and late fees, which will be recorded in the 2025 financial results, expected to reduce the company's net profit for that year [8] - China Pharmaceutical's wholly-owned subsidiary, Hainan Tongyong Sanyang Pharmaceutical and Hainan Kangli Pharmaceutical, received tax notices requiring a total payment of approximately 65.2178 million yuan in taxes and late fees, which will also impact the company's net profit for 2025 [9][10] Group 5: Regulatory Issues - Platelite has received a notice from the China Securities Regulatory Commission regarding a case of suspected illegal information disclosure, leading to an official investigation [11] Group 6: Legal Matters - Baotailong announced that its subsidiary, Shuangyashan Longmei Tiantai Coal Chemical Co., is involved in a significant lawsuit that has entered the second instance, with a ruling requiring it to pay 316 million yuan in contract price and interest, while also receiving compensation and a return of a quality guarantee deposit [12]

(本文来自第一财经) ST路通：股东吴爱军拟减持不超3%公司股份 凌志软件：股东周颖、梁启华拟合计减持不超1.43%公司股份 绿岛风：股东振中投资拟减持不超1%公司股份 双林股份：董事陈有甫拟减持不超0.02%公司股份 健之佳：实际控制人的一致行动人云南祥群拟5000万元增持公司股份 ...

证券代码：605266 证券简称：健之佳 公告编号：2026-001 健之佳医药连锁集团股份有限公司 关于实际控制人的一致行动人以自有资金及专项贷款增持公司股份 计划的公告 重要内容提示： 增持主体的基本情况：健之佳医药连锁集团股份有限公司（以下简称"公 司"）实际控制人之一蓝波 100%控股的云南祥群投资有限公司（以下简称"云南 祥群"）持有公司 13,818,299 股股份，占公司总股本的 8.9414%。含云南祥群在 内，公司实际控制人蓝波、舒畅夫妇及其一致行动人合计持有公司 63,007,569 股股份，占公司总股本的 40.7703%。 增持计划的主要内容：近日，公司收到云南祥群的《关于增持公司股份 的告知函》，云南祥群拟自本公告披露日起 6 个月内通过上海证券交易所交易系 统以集中竞价交易方式增持公司 A 股股份，增持总金额 5,000 万元，资金来源为 自有资金及股票增持专项贷款。 本次增持计划不触及要约收购，不会导致公司控股股东及实际控制人发生变 化。 增持计划无法实施风险：可能存在因资本市场变化等目前尚无法预判的 因素，导致本次增持计划无法按期完成的风险，敬请广大投资者注意投资风险。 | 增 ...

MACD金叉信号形成，这些股涨势不错！ 格隆汇12月31日丨健之佳(605266.SH)公布，近日，公司收到云南祥群的《关于增持公司股份的告知 函》，云南祥群拟自本公告披露日起6个月内通过上海证券交易所交易系统以集中竞价交易方式增持公 司A股股份，增持总金额5,000万元，资金来源为自有资金及股票增持专项贷款。 ...